Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas

Chimeric antigen receptor (CAR)-T cells targeting CD30 have demonstrated high response rates with durable remissions observed in a subset of patients with relapsed/refractory CD30+ hematologic malignancies, particularly classical Hodgkin lymphoma. This therapy has low rates of toxicity including cyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Tschernia, Nicholas P, Heiling, Hillary, Deal, Allison M, Cheng, Catherine, Babinec, Caroline, Gonzalez, Megan, Morrison, J Kaitlin, Dittus, Christopher, Dotti, Gianpietro, Beaven, Anne W, Serody, Jonathan S, Wood, William A, Savoldo, Barbara, Grover, Natalie S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394544/
https://www.ncbi.nlm.nih.gov/pubmed/37527906
http://dx.doi.org/10.1136/jitc-2023-006959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394544/
https://www.ncbi.nlm.nih.gov/pubmed/37527906
http://dx.doi.org/10.1136/jitc-2023-006959

Ejemplares similares